FDC (NSE:FDC) Net Margin % : 17.29% (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is FDC Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. FDC's Net Income for the three months ended in Dec. 2023 was ₹792 Mil. FDC's Revenue for the three months ended in Dec. 2023 was ₹4,582 Mil. Therefore, FDC's net margin for the quarter that ended in Dec. 2023 was 17.29%.

The historical rank and industry rank for FDC's Net Margin % or its related term are showing as below:

NSE:FDC' s Net Margin % Range Over the Past 10 Years
Min: 10.91 Med: 16.53 Max: 22.77
Current: 15.17

NSE:FDC's Net Margin % is ranked better than
81.55% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 3.53 vs NSE:FDC: 15.17

FDC Net Margin % Historical Data

The historical data trend for FDC's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FDC Net Margin % Chart

FDC Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Margin %

Get a 7-Day Free Trial

15.69

17.96

22.77

14.21

10.91

FDC Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															9.96	7.16	20.49	14.36	17.29

Competitive Comparison of FDC's Net Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, FDC's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FDC's Net Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, FDC's Net Margin % distribution charts can be found below:

* The bar in red indicates where FDC's Net Margin % falls into.

FDC Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

FDC's Net Margin for the fiscal year that ended in Mar. 2023 is calculated as

Net Margin	=	Net Income (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	1940.374	/	17778.284
	=	10.91 %

FDC's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	792.338	/	4581.681
	=	17.29 %

FDC (NSE:FDC) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

FDC Net Margin % Related Terms

Thank you for viewing the detailed overview of FDC's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

FDC (NSE:FDC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FDC Ltd (NSE:FDC) » Definitions » Net Margin %

Traded in Other Exchanges

531599:India

Address

C-3 Skyvistas, Near Versova Police Station, D.N. Nagar, Andheri (West), Mumbai, MH, IND, 400053

Website

https://www.fdcindia.com

FDC Ltd is an Indian-based pharmaceutical company with USFDA and UK-MHRA-approved API and formulations manufacturing facilities. It has its presence in numerous therapeutic segments: Anti-infectives, Gastro-Intestinal, Vitamins/Minerals/Nutrients, Ophthalmology/Otologicals, Cardiac, Dermatology, Respiratory, Gynaecology, and Others. The company's brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl, and Mycoderm. The majority of the revenue is generated domestically.